MAPT and Huntington disease: Thus a PET imaging agent for mHTT could be expected to have similar benefits to the amyloid, tau and α-synuclein PET imaging agents currently used for dementia imaging (Mathis et al., 2017), allowing diagnosis of HD, monitoring of disease progression, and evaluating patient response to HD modifying therapies targeting mHTT.